EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 15-Dec-2025 09:11 ET (15-Dec-2025 14:11 GMT/UTC)

6-Dec-2025

Continuous and fixed-duration treatments result in similar outcomes for CLL

American Society of Hematology
Reports and Proceedings

According to a new trial, patients with chronic lymphocytic leukemia show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

American Society of Hematology
Reports and Proceedings

Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term outcomes for patients with acute myeloid leukemia (AML), according to a new study from the HARMONY Alliance.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

American Society of Hematology
Reports and Proceedings

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation. The findings could allow more patients to avoid TBI and its associated long-term side effects.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

American Society of Hematology
Reports and Proceedings

Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child’s treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

American Society of Hematology
Reports and Proceedings

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

5-Dec-2025

Although public overwhelmingly supports hepatitis B vaccine for a newborn, partisan differences exist

Annenberg Public Policy Center of the University of Pennsylvania
Reports and Proceedings

Most Americans would be likely to recommend the hepatitis B vaccine for a newborn, according to a new survey by the Annenberg Public Policy Center.

5-Dec-2025

UCLA study uncovers how a key protein helps breast cancer cells survive in hostile conditions

University of California - Los Angeles Health Sciences
Peer-Reviewed Publication

By understanding the structure and function of NBCn1, the study provides a blueprint for designing drugs that could potentially block this transporter and disrupt the internal chemical balance that cancer cells depend on.

Journal: Nature Communications
Funder: NIH/National Institutes of Health, The Smidt Family Foundation, The Kleeman Fund, The Factor Family Foundation

5-Dec-2025

Next-generation targeted alpha therapy using astatine shows promise in thyroid cancer resistant to conventional treatment

Society of Nuclear Medicine and Molecular Imaging
Peer-Reviewed Publication

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide ²¹¹At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs. The findings were published in the December issue of The Journal of Nuclear Medicine.

Journal: Journal of Nuclear Medicine

5-Dec-2025

A new tunable cell-sorting device with potential biomedical applications

Institute of Science Tokyo
Peer-Reviewed Publication

Poly(N-isopropylacrylamide) (PNIPAM) hydrogel undergoes significant but precise changes in size between 20 and 40 °C, making it an excellent candidate for use in variable-size deterministic lateral displacement (DLD) array devices. Researchers from Science Tokyo have built a tunable DLD cell-sorting platform and verified its ability to sort cancer cells of defined sizes from blood samples. This platform could offer high-resolution size-based cell sorting for a wide variety of biomedical applications

Journal: Lab on a Chip
Funder: Japan Society for the Promotion of Science

5-Dec-2025

AI data processing meets privacy at the Josep Carreras Institute

Josep Carreras Leukaemia Research Institute
Business Announcement

The SECURED project aims at generating libraries and machine learning tools to foster innovation in the fight against blood cancers while preserving the highest privacy standards for sensitive patient data. Dr Eduard Porta, head of the Cancer Immunogenomics team at the Josep Carreras Leukaemia Research Institute is part of this Horizon Europe-funded collaboration that will bring the most sophisticated technologies into the real world.